Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Financials

$26.62 -0.08 (-0.30%)

As of 05/2/2025 04:00 PM Eastern

Annual Income Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

This table shows Harrow Health, Inc. 11.875% Senior Notes due 2027's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-10	-16	-19	-12	15	0.17	-3.36	-18	-14	-24	-17
Consolidated Net Income / (Loss)	-10	-16	-19	-12	15	-0.13	-3.42	-18	-14	-24	-17
Net Income / (Loss) Continuing Operations	-10	-16	-19	-12	15	-0.13	-3.42	-18	-14	-24	-17
Total Pre-Tax Income	-10	-16	-19	-13	15	-0.12	-3.42	-18	-14	-24	-17
Total Operating Income	-10	-15	-16	-12	-5.22	-4.80	0.39	1.61	1.92	0.43	8.82
Total Gross Profit	0.57	4.51	10	13	25	34	34	54	63	91	150
Total Revenue	1.66	9.72	20	27	41	51	49	72	89	130	200
Operating Revenue	1.66	9.72	20	27	41	51	49	72	89	130	200
Total Cost of Revenue	1.09	5.21	9.83	14	17	17	14	18	25	40	49
Operating Cost of Revenue	1.09	5.21	9.83	14	17	17	14	18	25	40	49
Total Operating Expenses	11	19	26	25	30	39	34	53	61	90	142
Selling, General & Admin Expense	8.09	13	18	25	29	33	31	41	58	83	129
Research & Development Expense	0.24	0.33	0.74	0.41	0.83	2.08	2.41	11	3.05	6.65	12
Impairment Charge	-	0.00	0.30	-	0.00	4.04	0.36	0.25	0.00	0.38	0.25
Total Other Income / (Expense), net	0.03	-1.08	-3.32	-0.76	20	4.68	-3.80	-19	-16	-24	-26
Interest Expense	-0.03	1.11	4.74	3.03	2.73	2.50	2.24	6.19	7.24	27	23
Interest & Investment Income	-	-	0.00	3.51	23	6.55	3.26	-10	-2.91	3.09	-3.17
Other Income / (Expense), net	0.00	0.03	1.42	-1.24	-0.29	0.63	-4.82	-3.17	-5.77	-0.44	-0.19
Income Tax Expense	-	0.00	-0.11	-0.94	0.00	0.01	0.00	0.13	0.08	0.70	0.16
Basic Earnings per Share	($1.11)	($1.66)	($1.50)	($0.60)	$0.67	$0.01	($0.13)	($0.69)	($0.51)	($0.75)	($0.49)
Weighted Average Basic Shares Outstanding	9.13M	9.58M	12.74M	20.03M	21.92M	25.32M	25.90M	26.76M	27.46M	32.62M	35.65M
Diluted Earnings per Share	($1.11)	($1.66)	($1.50)	($0.60)	$0.61	$0.01	($0.13)	-	($0.51)	($0.75)	($0.49)
Weighted Average Diluted Shares Outstanding	9.13M	9.58M	12.74M	20.03M	23.81M	26.47M	25.90M	26.76M	27.46M	32.62M	35.65M
Weighted Average Basic & Diluted Shares Outstanding	9.13M	9.58M	12.74M	20.03M	24.69M	25.53M	25.90M	26.76M	29.97M	35.36M	35.65M

This table shows Harrow Health, Inc. 11.875% Senior Notes due 2027's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Income / (Loss) Attributable to Common Shareholders	-6.46	1.06	-6.64	-4.23	-4.39	-9.15	-14	-6.47	-4.22	6.78
Consolidated Net Income / (Loss)	-6.46	1.06	-6.64	-4.23	-4.39	-9.15	-14	-6.47	-4.22	6.78
Net Income / (Loss) Continuing Operations	-6.46	1.06	-6.64	-4.23	-4.39	-9.15	-14	-6.47	-4.22	6.78
Total Pre-Tax Income	-6.43	1.06	-6.93	-4.24	-2.85	-9.68	-14	-5.82	-4.20	6.26
Total Operating Income	-0.09	-1.78	1.21	2.35	1.74	-4.88	-6.93	1.53	1.32	13
Total Gross Profit	16	14	18	23	24	25	24	36	37	53
Total Revenue	23	20	26	33	34	36	35	49	49	67
Operating Revenue	23	20	26	33	34	36	35	49	49	67
Total Cost of Revenue	6.72	6.17	8.27	10	10	11	11	13	12	14
Operating Cost of Revenue	6.72	6.17	8.27	10	10	11	11	13	12	14
Total Operating Expenses	16	16	17	21	22	30	31	35	36	40
Selling, General & Admin Expense	15	15	16	20	21	26	29	32	34	35
Research & Development Expense	0.78	0.70	0.73	1.16	1.42	3.34	2.15	3.05	2.27	4.76
Total Other Income / (Expense), net	-6.34	2.83	-8.14	-6.60	-4.60	-4.81	-6.64	-7.35	-5.52	-6.64
Interest Expense	1.80	1.86	10	5.70	5.75	5.12	5.42	5.47	5.53	6.38
Other Income / (Expense), net	-3.50	3.26	0.03	-0.18	-0.20	-0.10	0.03	0.05	0.00	-0.26
Income Tax Expense	0.04	-	-0.29	-0.02	1.54	-0.54	0.00	0.66	0.02	-0.51
Basic Earnings per Share	($0.24)	$0.05	($0.22)	($0.14)	($0.13)	($0.26)	($0.38)	($0.18)	($0.12)	$0.19
Weighted Average Basic Shares Outstanding	27.35M	27.46M	30.29M	30.46M	34.26M	32.62M	35.47M	35.62M	35.70M	35.65M
Diluted Earnings per Share	($0.24)	-	($0.22)	($0.14)	($0.13)	($0.26)	($0.38)	($0.18)	($0.12)	$0.19
Weighted Average Diluted Shares Outstanding	27.35M	27.46M	30.29M	30.46M	34.26M	32.62M	35.47M	35.62M	35.70M	35.65M
Weighted Average Basic & Diluted Shares Outstanding	27.41M	29.97M	30.12M	35.12M	35.12M	35.36M	35.38K	35.48M	35.61M	35.65M

This table details how cash moves in and out of Harrow Health, Inc. 11.875% Senior Notes due 2027's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Net Change in Cash & Equivalents	-7.37	-5.53	6.17	-6.60	2.62	-1.89	-0.65	38	54	-22	-27
Net Cash From Operating Activities	-7.06	-11	-11	-8.80	0.69	0.95	-1.10	5.08	1.71	3.84	-22
Net Cash From Continuing Operating Activities	-7.06	-11	-11	-11	0.69	0.95	-1.10	5.08	1.71	3.84	-22
Net Income / (Loss) Continuing Operations	-10	-16	-19	-12	15	-0.13	-3.42	-18	-14	-24	-17
Consolidated Net Income / (Loss)	-10	-16	-19	-12	15	-0.13	-3.42	-18	-14	-24	-17
Depreciation Expense	0.04	0.26	1.06	1.40	1.61	1.94	1.88	1.72	1.48	1.53	1.85
Amortization Expense	0.05	0.64	1.32	1.34	0.85	1.24	1.32	1.36	2.97	15	17
Non-Cash Adjustments To Reconcile Net Income	2.62	3.54	6.18	-0.26	-20	-0.38	5.39	20	17	19	21
Changes in Operating Assets and Liabilities, net	0.36	0.33	-0.68	0.70	3.44	-1.72	-6.27	-0.25	-5.57	-7.14	-45
Net Cash From Investing Activities	-0.91	-5.13	-7.29	-0.96	-2.20	-1.83	-0.98	-19	-1.74	-153	-33
Net Cash From Continuing Investing Activities	-0.91	-2.09	-7.29	-0.96	-2.20	-1.83	-0.98	-19	-1.74	-153	-33
Purchase of Property, Plant & Equipment	-0.17	-1.52	-6.89	-0.77	-1.77	-1.47	-0.86	-1.79	-2.60	-1.46	-1.60
Acquisitions	-0.64	-3.61	-0.35	-0.25	-0.44	-0.37	-0.13	-0.08	-0.18	-0.02	-0.08
Sale and/or Maturity of Investments	-	-	-	-	-	-	0.00	9.83	-	0.00	5.51
Other Investing Activities, net	-	-	0.00	-0.05	0.00	-	0.00	-27	1.00	-151	-37
Net Cash From Financing Activities	0.60	11	25	4.93	4.13	-1.01	1.43	51	54	127	29
Net Cash From Continuing Financing Activities	0.63	11	25	4.93	4.13	-1.01	1.43	51	54	127	29
Repayment of Debt	-0.01	-0.16	-0.46	-15	-0.74	-1.49	-1.51	-16	-0.02	-60	0.00
Issuance of Debt	-	9.27	4.71	16	-	0.00	2.97	71	32	134	30
Issuance of Common Equity	0.00	0.40	21	4.06	0.64	-	-	0.00	23	65	0.00
Other Financing Activities, net	0.62	1.24	-0.09	0.18	4.23	0.49	-0.03	-3.16	-0.23	-13	-1.25
Cash Interest Paid	0.00	0.64	1.37	1.54	2.10	1.97	1.79	4.82	6.48	19	21
Cash Income Taxes Paid	0.00	0.00	0.01	0.01	0.00	0.02	0.00	0.01	0.08	0.00	0.37

This table details how cash moves in and out of Harrow Health, Inc. 11.875% Senior Notes due 2027's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Net Change in Cash & Equivalents	-1.48	51	-77	3.51	43	8.48	-5.55	2.43	1.63	-25
Net Cash From Operating Activities	-0.41	-3.71	-8.21	4.57	-1.21	8.70	-4.63	-2.75	2.95	-18
Net Cash From Continuing Operating Activities	-0.41	-3.71	-8.21	4.57	-1.21	8.70	-4.63	-2.75	2.95	-18
Net Income / (Loss) Continuing Operations	-6.46	1.06	-6.64	-4.23	-4.39	-9.15	-14	-6.47	-4.22	6.78
Consolidated Net Income / (Loss)	-6.46	1.06	-6.64	-4.23	-4.39	-9.15	-14	-6.47	-4.22	6.78
Depreciation Expense	0.25	0.39	0.29	0.40	0.41	0.44	0.43	0.45	0.50	0.47
Amortization Expense	0.77	0.75	3.15	3.89	3.71	4.16	3.72	3.72	3.88	5.56
Non-Cash Adjustments To Reconcile Net Income	6.47	-2.44	5.08	6.14	3.19	4.55	5.33	6.18	4.46	5.19
Changes in Operating Assets and Liabilities, net	-1.43	-3.46	-10	-1.62	-4.12	8.70	-0.55	-6.63	-1.67	-36
Net Cash From Investing Activities	-1.07	-0.01	-131	-1.25	-20	-0.20	-0.11	5.10	-0.60	-38
Net Cash From Continuing Investing Activities	-1.07	-0.01	-131	-1.25	-20	-0.20	-0.11	5.10	-0.60	-38
Purchase of Property, Plant & Equipment	-1.06	-0.88	-0.50	-0.25	-0.52	-0.19	-0.09	-0.34	-0.60	-0.56
Acquisitions	-0.01	-0.16	0.00	-	-	-0.02	-0.02	-0.06	0.01	-0.01
Other Investing Activities, net	-	1.00	-130	-1.00	-20	0.01	0.00	-	-	-37
Net Cash From Financing Activities	-	55	62	0.19	64	-0.02	-0.81	0.07	-0.72	30
Net Cash From Continuing Financing Activities	-	55	62	0.19	64	-0.02	-0.81	0.07	-0.72	30
Repayment of Debt	-	-0.02	-60	-	-	-	0.00	-0.10	-	0.10
Issuance of Debt	-	32	117	4.96	-62	74	0.00	-	-	30
Other Financing Activities, net	-	0.65	4.45	-4.77	61	-74	-0.81	0.17	-0.72	0.11
Cash Interest Paid	1.62	1.63	3.37	4.71	4.20	6.61	5.34	4.98	5.24	5.04
Cash Income Taxes Paid	0.04	-	0.00	0.00	-0.00	-	0.00	-	-	0.37

This table presents Harrow Health, Inc. 11.875% Senior Notes due 2027's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Total Assets	10	14	27	24	49	59	57	98	157	312	389
Total Current Assets	9.06	5.87	15	8.81	33	36	41	61	118	139	190
Cash & Equivalents	8.21	2.69	8.85	-	-	-	-	42	96	74	47
Short-Term Investments	-	-	-	0.00	21	25	28	8.50	5.59	8.68	0.00
Accounts Receivable	0.08	0.84	2.92	1.53	1.91	2.01	2.66	4.47	6.25	36	116
Inventories, net	0.37	1.41	1.84	2.25	1.83	3.30	3.96	4.22	6.54	11	11
Prepaid Expenses	0.24	0.79	0.94	0.71	0.84	0.59	1.60	1.31	3.61	9.59	15
Plant, Property, & Equipment, net	0.24	2.66	7.30	6.22	6.38	5.38	3.87	3.14	3.49	3.52	3.73
Total Noncurrent Assets	0.94	5.60	5.20	8.90	10	18	13	35	36	169	196
Goodwill	0.33	2.47	2.23	2.23	2.23	0.33	0.33	0.33	0.33	0.33	0.33
Intangible Assets	0.61	3.14	2.97	2.86	3.06	2.34	2.52	17	26	162	187
Other Noncurrent Operating Assets	-	-	0.00	3.51	4.95	15	9.77	5.94	9.46	6.79	8.55
Total Liabilities & Shareholders' Equity	10	14	27	24	49	59	57	98	157	312	389
Total Liabilities	2.09	16	21	21	25	32	31	87	130	242	320
Total Current Liabilities	1.56	5.37	9.91	5.77	12	12	11	9.72	19	49	91
Short-Term Debt	0.06	0.50	4.43	0.60	2.53	1.77	3.90	0.28	0.72	-	0.50
Accounts Payable	0.79	3.41	3.54	3.89	6.25	7.70	3.93	6.34	14	25	41
Accrued Expenses	0.00	0.20	0.21	0.05	-	-	-	-	0.00	18	40
Current Deferred Revenue	-	-	-	0.03	0.12	0.06	0.07	0.02	0.11	0.08	0.04
Current Employee Benefit Liabilities	0.72	1.20	1.64	1.21	2.28	2.12	2.32	3.09	4.03	5.45	9.50
Total Noncurrent Liabilities	0.53	10	11	16	13	19	20	78	112	192	228
Long-Term Debt	0.00	8.34	7.94	14	12	12	12	72	104	186	220
Other Noncurrent Operating Liabilities	0.51	0.76	0.72	0.80	0.80	7.14	7.45	6.01	0.00	6.52	8.79
Commitments & Contingencies	0.00	-	-	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	8.15	-1.39	6.43	2.62	25	27	27	11	27	70	69
Total Preferred & Common Equity	8.15	-1.39	6.43	2.62	25	28	27	11	28	71	70
Total Common Equity	8.15	-1.39	6.43	2.62	25	28	27	11	28	71	70
Common Stock	50	56	83	91	99	102	105	107	137	205	221
Retained Earnings	-42	-58	-77	-89	-74	-74	-77	-95	-109	-134	-151
Noncontrolling Interest	-	-	-	-	0.00	-0.29	-0.36	-0.36	-0.36	-0.36	-0.36

This table presents Harrow Health, Inc. 11.875% Senior Notes due 2027's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Period end date	9/30/2022	3/31/2023	6/30/2023	9/30/2023	3/31/2024	6/30/2024	9/30/2024
Total Assets	99	217	224	286	296	307	352
Total Current Assets	64	52	60	110	125	139	147
Cash & Equivalents	45	19	23	66	69	71	73
Short-Term Investments	4.16	7.63	6.92	8.27	7.43	0.00	0.00
Accounts Receivable	6.74	12	18	18	29	52	54
Inventories, net	5.28	9.09	8.56	8.92	11	9.43	10
Prepaid Expenses	2.93	3.60	3.81	9.01	9.72	7.01	11
Plant, Property, & Equipment, net	3.29	3.59	3.63	3.63	3.39	3.29	3.63
Total Noncurrent Assets	32	162	160	172	167	164	201
Goodwill	0.33	0.33	0.33	0.33	0.33	0.33	0.33
Intangible Assets	22	154	152	165	159	157	191
Other Noncurrent Operating Assets	7.69	7.34	7.16	6.97	6.97	6.77	9.38
Total Liabilities & Shareholders' Equity	99	217	224	286	296	307	352
Total Liabilities	98	196	202	211	235	248	294
Total Current Liabilities	18	18	23	19	42	54	95
Short-Term Debt	0.70	0.74	0.76	0.79	0.80	0.77	38
Accounts Payable	14	14	18	13	15	22	25
Accrued Expenses	-	-	-	-	21	25	25
Current Deferred Revenue	0.12	0.07	0.13	0.15	0.11	0.25	0.14
Current Employee Benefit Liabilities	3.44	3.10	4.29	5.32	5.03	5.72	7.19
Total Noncurrent Liabilities	80	178	179	192	194	195	199
Long-Term Debt	72	169	170	182	184	185	186
Capital Lease Obligations	7.52	7.14	6.94	6.74	6.72	6.54	9.50
Noncurrent Deferred & Payable Income Tax Liabilities	-	-	-	-	-	0.62	0.64
Other Noncurrent Operating Liabilities	-	2.28	2.28	2.71	2.71	2.71	2.71
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	0.86	22	22	75	60	58	58
Total Preferred & Common Equity	1.22	22	22	76	61	59	58
Total Common Equity	1.22	22	22	76	61	59	58
Common Stock	112	138	143	201	208	212	216
Retained Earnings	-111	-116	-120	-125	-147	-154	-158
Noncontrolling Interest	-0.36	-0.36	-0.36	-0.36	-0.36	-0.36	-0.36

This table displays calculated financial ratios and metrics derived from Harrow Health, Inc. 11.875% Senior Notes due 2027's official financial filings.

Metric	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Period end date	12/31/2014	12/31/2015	12/31/2016	12/31/2017	12/31/2018	12/31/2019	12/31/2020	12/31/2021	12/31/2022	12/31/2023	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	16,500.00%	485.30%	105.25%	34.26%	54.52%	23.67%	-4.48%	48.30%	22.24%	46.95%	53.32%
EBITDA Growth	-30.99%	-38.14%	13.08%	11.79%	71.37%	67.55%	-24.65%	222.93%	-60.84%	2,664.98%	66.70%
EBIT Growth	-32.00%	-45.77%	2.25%	7.31%	58.91%	24.37%	-6.46%	64.91%	-147.62%	99.66%	66,538.46%
NOPAT Growth	-32.00%	-46.07%	-7.15%	23.42%	38.73%	35.66%	108.03%	319.22%	18.90%	-77.54%	1,946.87%
Net Income Growth	-32.38%	-57.14%	-20.05%	37.21%	222.03%	-100.85%	-2,635.20%	-426.67%	21.77%	-73.30%	28.39%
EPS Growth	-26.14%	-49.55%	9.64%	60.00%	201.67%	-98.36%	-1,400.00%	0.00%	0.00%	-47.06%	34.67%
Operating Cash Flow Growth	-58.98%	-57.90%	-0.65%	21.51%	107.80%	38.28%	-215.79%	562.00%	-66.45%	125.22%	-678.18%
Free Cash Flow Firm Growth	-52.71%	-102.19%	-16.04%	12.36%	66.63%	66.26%	206.12%	-386.98%	-187.99%	-792.54%	54.00%
Invested Capital Growth	73.59%	3,472.99%	139.45%	62.14%	-0.46%	-9.09%	-9.66%	43.68%	78.48%	361.39%	39.51%
Revenue Q/Q Growth	49.21%	43.66%	12.97%	6.12%	55.62%	-15.69%	136.50%	-22.15%	0.16%	14.04%	18.02%
EBITDA Q/Q Growth	-8.93%	-14.06%	11.37%	22.53%	74.50%	-115.56%	92.62%	-93.72%	108.04%	-15.44%	228.52%
EBIT Q/Q Growth	-9.22%	-15.14%	7.84%	15.84%	63.26%	-220.72%	77.82%	-107.39%	66.42%	-100.20%	196.22%
NOPAT Q/Q Growth	-9.22%	-15.10%	6.95%	10.04%	53.26%	-217.57%	101.40%	-96.49%	-1.18%	-87.78%	198.55%
Net Income Q/Q Growth	-9.32%	-17.60%	-5.40%	21.75%	185.95%	-100.48%	79.11%	-463.70%	37.56%	-71.81%	47.67%
EPS Q/Q Growth	-9.90%	-17.73%	6.25%	34.07%	303.33%	-98.53%	-85.71%	0.00%	0.00%	0.00%	47.87%
Operating Cash Flow Q/Q Growth	-13.04%	-12.61%	8.66%	18.09%	60.14%	228.73%	-198.39%	-15.38%	-56.58%	144.82%	-619.59%
Free Cash Flow Firm Q/Q Growth	-9.18%	-12.43%	9.03%	-19.84%	67.69%	-124.37%	110.21%	-119.86%	-70.95%	14.52%	-88.36%
Invested Capital Q/Q Growth	24.29%	8.32%	-4.80%	19.60%	-9.50%	4.88%	3.22%	6.11%	24.93%	-9.26%	11.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	34.16%	46.42%	50.70%	49.56%	60.07%	67.26%	70.41%	74.87%	71.35%	69.55%	75.33%
EBITDA Margin	-606.14%	-143.06%	-60.59%	-39.81%	-7.37%	-1.93%	-2.53%	2.09%	0.67%	12.62%	13.72%
Operating Margin	-611.27%	-152.55%	-79.64%	-45.43%	-12.61%	-9.37%	0.79%	2.23%	2.17%	0.33%	4.42%
EBIT Margin	-611.27%	-152.23%	-72.50%	-50.05%	-13.31%	-8.14%	-9.07%	-2.15%	-4.35%	-0.01%	4.33%
Profit (Net Income) Margin	-609.52%	-163.64%	-95.71%	-44.76%	35.35%	-0.24%	-7.00%	-24.85%	-15.90%	-18.75%	-8.76%
Tax Burden Percent	100.00%	100.00%	99.42%	92.76%	100.00%	106.84%	100.12%	100.74%	100.54%	102.96%	100.93%
Interest Burden Percent	99.71%	107.49%	132.78%	96.41%	-265.57%	2.81%	77.02%	1,148.71%	363.64%	182,384.62%	-200.53%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-462.77%	-141.75%	-58.71%	-29.15%	-19.69%	1.74%	6.32%	4.58%	0.29%	2.97%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	21.54%	-291.57%	-93.49%	441.38%	-55.45%	33.34%	1,900.12%	-145.87%	-43.27%	-14.18%
Return on Net Nonoperating Assets (RNNOA)	0.00%	-7.26%	-614.62%	-206.24%	136.03%	19.21%	-14.35%	-101.70%	-78.38%	-50.28%	-28.00%
Return on Equity (ROE)	-87.00%	-470.04%	-756.37%	-264.95%	106.88%	-0.48%	-12.61%	-95.38%	-73.80%	-50.00%	-25.03%
Cash Return on Invested Capital (CROIC)	0.00%	-327.49%	-223.91%	-106.12%	-28.69%	-10.16%	11.90%	-29.53%	-51.79%	-128.46%	-30.02%
Operating Return on Assets (OROA)	-78.04%	-121.37%	-69.88%	-52.38%	-15.01%	-7.67%	-7.61%	-2.00%	-3.01%	-0.01%	2.46%
Return on Assets (ROA)	-77.82%	-130.46%	-92.26%	-46.85%	39.87%	-0.23%	-5.87%	-23.12%	-11.02%	-10.40%	-4.99%
Return on Common Equity (ROCE)	-87.00%	-470.04%	-756.37%	-264.95%	106.88%	-0.48%	-12.76%	-97.17%	-75.18%	-50.36%	-25.15%
Return on Equity Simple (ROE_SIMPLE)	-124.15%	1,147.94%	-296.75%	-458.32%	59.09%	-0.45%	-12.58%	-159.55%	-51.05%	-34.50%	-25.10%
Net Operating Profit after Tax (NOPAT)	-7.10	-10	-11	-8.51	-5.22	-3.36	0.27	1.13	1.34	0.30	6.18
NOPAT Margin	-427.89%	-106.79%	-55.75%	-31.80%	-12.61%	-6.56%	0.55%	1.56%	1.52%	0.23%	3.09%
Net Nonoperating Expense Percent (NNEP)	-25.21%	-484.31%	149.82%	34.78%	-470.52%	35.76%	-31.60%	-1,893.80%	150.45%	43.55%	17.15%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-	-	-	0.12%	2.13%
Cost of Revenue to Revenue	65.84%	53.58%	49.30%	50.44%	39.93%	32.74%	29.59%	25.13%	28.65%	30.45%	24.67%
SG&A Expenses to Revenue	487.17%	128.69%	88.10%	93.45%	70.68%	64.67%	63.94%	57.01%	65.74%	63.82%	64.66%
R&D to Revenue	14.28%	3.42%	3.71%	1.54%	1.99%	4.07%	4.94%	15.29%	3.44%	5.11%	6.13%
Operating Expenses to Revenue	645.42%	198.97%	130.34%	94.99%	72.68%	76.64%	69.62%	72.64%	69.18%	69.22%	70.91%
Earnings before Interest and Taxes (EBIT)	-10	-15	-14	-13	-5.51	-4.17	-4.43	-1.56	-3.85	-0.01	8.64
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-10	-14	-12	-11	-3.05	-0.99	-1.23	1.52	0.59	16	27
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	8.52	0.00	5.15	13.35	5.35	7.07	6.50	20.60	14.66	5.56	17.15
Price to Tangible Book Value (P/TBV)	9.63	0.00	26.87	0.00	6.80	7.82	7.26	0.00	283.75	0.00	0.00
Price to Revenue (P/Rev)	41.82	6.91	1.66	1.30	3.20	3.83	3.61	3.21	4.57	3.02	5.99
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	9.06	1,165.75	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	11.04%	0.09%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	15.82	3.41	2.80	7.03	11.36	11.19	11.50	11.02	2.86	5.65
Enterprise Value to Revenue (EV/Rev)	36.82	7.52	1.89	1.88	3.03	3.60	3.36	3.34	4.68	3.81	6.85
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	159.67	698.05	30.20	49.94
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	158.31
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	608.91	214.40	308.67	1,644.29	221.41
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	182.77	194.07	0.00	47.66	243.19	129.19	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	89.26	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.01	-6.38	2.13	5.86	0.59	0.51	0.61	6.58	4.12	2.64	3.18
Long-Term Debt to Equity	0.00	-6.02	1.44	5.63	0.48	0.45	0.46	6.56	4.09	2.64	3.17
Financial Leverage	-1.03	-0.34	2.11	2.21	0.31	-0.35	-0.43	-0.05	0.54	1.16	1.97
Leverage Ratio	1.12	3.60	8.20	5.66	2.68	2.08	2.15	4.13	6.70	4.81	5.02
Compound Leverage Factor	1.11	3.87	10.89	5.45	-7.12	0.06	1.65	47.40	24.36	8,769.72	-10.06
Debt to Total Capital	0.90%	118.58%	68.03%	85.42%	36.99%	33.83%	37.78%	86.81%	80.47%	72.53%	76.05%
Short-Term Debt to Total Capital	0.67%	6.76%	22.03%	3.33%	6.44%	4.28%	9.04%	0.34%	0.52%	0.00%	0.17%
Long-Term Debt to Total Capital	0.23%	111.82%	46.00%	82.09%	30.55%	29.55%	28.74%	86.47%	79.95%	72.53%	75.88%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	-0.71%	-0.82%	-0.43%	-0.25%	-0.14%	-0.12%
Common Equity to Total Capital	99.10%	-18.58%	31.97%	14.58%	63.01%	66.88%	63.04%	13.62%	19.79%	27.61%	24.07%
Debt to EBITDA	-0.01	-0.64	-1.13	-1.44	-4.76	-14.16	-13.20	47.43	188.94	11.32	8.04
Net Debt to EBITDA	0.82	-0.43	-0.38	-1.44	2.26	11.30	9.86	6.68	17.46	6.28	6.31
Long-Term Debt to EBITDA	0.00	-0.60	-0.77	-1.38	-3.93	-12.37	-10.04	47.24	187.72	11.32	8.02
Debt to NOPAT	-0.01	-0.85	-1.23	-1.80	-2.78	-4.18	60.46	63.68	83.55	616.13	35.63
Net Debt to NOPAT	1.17	-0.58	-0.42	-1.80	1.32	3.33	-45.13	8.98	7.72	341.79	27.98
Long-Term Debt to NOPAT	0.00	-0.80	-0.83	-1.73	-2.30	-3.65	45.99	63.43	83.01	616.13	35.55
Altman Z-Score	11.96	-5.85	-3.80	-4.79	2.09	3.07	2.80	1.54	2.13	1.14	2.59
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	-0.56%	-1.19%	-1.88%	-1.86%	-0.73%	-0.51%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.81	1.09	1.49	1.53	2.76	2.93	3.80	6.24	6.35	2.83	2.08
Quick Ratio	5.32	0.66	1.19	0.28	1.96	2.22	2.88	5.67	5.80	2.41	1.79
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-7.48	-15	-18	-15	-5.14	-1.73	1.84	-5.28	-15	-136	-62
Operating Cash Flow to CapEx	-4,055.75%	-733.57%	-162.84%	-1,335.81%	38.86%	64.89%	-129.56%	284.55%	66.42%	263.01%	-1,391.97%
Free Cash Flow to Firm to Interest Expense	0.00	-13.66	-3.70	-5.09	-1.88	-0.69	0.82	-0.85	-2.10	-5.06	-2.74
Operating Cash Flow to Interest Expense	0.00	-10.06	-2.37	-2.91	0.25	0.38	-0.49	0.82	0.24	0.14	-0.97
Operating Cash Flow Less CapEx to Interest Expense	0.00	-11.43	-3.82	-3.13	-0.40	-0.21	-0.87	0.53	-0.12	0.09	-1.04
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.13	0.80	0.96	1.05	1.13	0.94	0.84	0.93	0.69	0.55	0.57
Accounts Receivable Turnover	0.00	21.10	10.60	12.03	24.03	26.08	20.93	20.32	16.53	6.13	2.62
Inventory Turnover	0.00	5.83	6.04	6.60	8.09	6.52	3.98	4.45	4.72	4.55	4.57
Fixed Asset Turnover	12.30	6.70	4.01	3.96	6.57	8.71	10.57	20.68	26.74	37.16	55.03
Accounts Payable Turnover	1.99	2.48	2.83	3.64	3.26	2.40	2.49	3.55	2.52	2.07	1.49
Days Sales Outstanding (DSO)	0.00	17.30	34.42	30.33	15.19	13.99	17.44	17.96	22.08	59.59	139.55
Days Inventory Outstanding (DIO)	0.00	62.57	60.39	55.27	45.10	55.95	91.65	81.95	77.35	80.15	79.93
Days Payable Outstanding (DPO)	183.49	147.02	128.93	100.31	111.96	152.02	146.80	102.89	144.57	176.57	244.55
Cash Conversion Cycle (CCC)	-183.49	-67.15	-34.12	-14.71	-51.67	-82.08	-37.71	-2.98	-45.14	-36.84	-25.06
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-0.14	4.62	11	18	18	16	15	21	38	174	242
Invested Capital Turnover	-5.06	4.33	2.54	1.85	2.31	3.00	3.16	4.06	3.02	1.23	0.96
Increase / (Decrease) in Invested Capital	0.38	4.76	6.44	6.88	-0.08	-1.62	-1.57	6.41	17	136	69
Enterprise Value (EV)	61	73	38	50	126	184	164	242	415	496	1,367
Market Capitalization	69	67	33	35	132	196	177	232	405	393	1,195
Book Value per Share	$0.88	($0.14)	$0.49	$0.13	$1.06	$1.10	$1.06	$0.42	$1.01	$2.02	$1.96
Tangible Book Value per Share	$0.78	($0.72)	$0.09	($0.12)	$0.84	$0.99	$0.94	($0.23)	$0.05	($2.61)	($3.30)
Total Capital	8.22	7.46	20	18	39	41	43	83	139	256	289
Total Debt	0.07	8.84	14	15	15	14	16	72	112	186	220
Total Long-Term Debt	0.02	8.34	9.26	15	12	12	12	72	112	186	220
Net Debt	-8.29	6.01	4.63	15	-6.89	-11	-12	10	10	103	173
Capital Expenditures (CapEx)	0.17	1.52	6.89	0.66	1.77	1.46	0.85	1.79	2.57	1.46	1.60
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-0.81	-1.83	0.23	3.63	2.05	0.33	5.63	0.55	-1.51	7.37	52
Debt-free Net Working Capital (DFNWC)	7.55	1.00	9.28	3.63	23	26	34	51	100	90	99
Net Working Capital (NWC)	7.50	0.50	4.85	3.03	21	24	30	51	100	90	98
Net Nonoperating Expense (NNE)	3.02	5.52	7.97	3.47	-20	-3.23	3.69	19	15	25	24
Net Nonoperating Obligations (NNO)	-8.29	6.01	4.63	15	-6.89	-11	-12	10	10	103	173
Total Depreciation and Amortization (D&A)	0.09	0.89	2.38	2.74	2.46	3.18	3.20	3.07	4.45	16	19
Debt-free, Cash-free Net Working Capital to Revenue	-48.80%	-18.86%	1.13%	13.56%	4.96%	0.65%	11.51%	0.76%	-1.70%	5.66%	25.83%
Debt-free Net Working Capital to Revenue	454.88%	10.32%	46.53%	13.56%	56.73%	49.90%	69.74%	70.67%	113.27%	69.23%	49.50%
Net Working Capital to Revenue	451.57%	5.14%	24.31%	11.32%	50.62%	46.44%	61.76%	70.29%	112.45%	69.23%	49.25%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.11)	($1.66)	($1.50)	$0.60	$0.67	$0.01	($0.13)	($0.69)	($0.51)	($0.75)	($0.49)
Adjusted Weighted Average Basic Shares Outstanding	9.34M	13.11M	18.63M	20.78M	21.92M	25.32M	25.90M	27.03M	27.46M	32.62M	35.65M
Adjusted Diluted Earnings per Share	($1.11)	($1.66)	($1.50)	$0.60	$0.61	$0.01	($0.13)	($0.69)	$0.00	($0.75)	($0.49)
Adjusted Weighted Average Diluted Shares Outstanding	9.34M	13.11M	18.63M	20.78M	23.81M	26.47M	25.90M	27.03M	29.97M	32.62M	35.65M
Adjusted Basic & Diluted Earnings per Share	($1.11)	($1.66)	($1.50)	$0.60	$0.00	$0.00	$0.00	($0.69)	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	9.13M	9.58M	12.74M	20.03M	24.69M	25.53M	25.98M	26.76M	29.97M	35.36M	35.65M
Normalized Net Operating Profit after Tax (NOPAT)	-7.10	-10	-11	-8.51	-3.65	-0.53	0.52	1.30	1.34	0.57	6.35
Normalized NOPAT Margin	-427.89%	-106.79%	-54.69%	-31.80%	-8.83%	-1.03%	1.07%	1.80%	1.52%	0.44%	3.18%
Pre Tax Income Margin	-609.52%	-163.64%	-96.27%	-48.26%	35.35%	-0.23%	-6.99%	-24.66%	-15.81%	-18.21%	-8.68%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-13.35	-3.05	-4.43	-2.02	-1.67	-1.98	-0.25	-0.53	0.00	0.38
NOPAT to Interest Expense	0.00	-9.36	-2.35	-2.81	-1.91	-1.34	0.12	0.18	0.19	0.01	0.27
EBIT Less CapEx to Interest Expense	0.00	-14.72	-4.50	-4.65	-2.67	-2.25	-2.36	-0.54	-0.89	-0.06	0.31
NOPAT Less CapEx to Interest Expense	0.00	-10.74	-3.80	-3.03	-2.56	-1.93	-0.26	-0.11	-0.17	-0.04	0.20
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.71%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.13%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.71%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Harrow Health, Inc. 11.875% Senior Notes due 2027's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Period end date	9/30/2022	12/31/2022	3/31/2023	6/30/2023	9/30/2023	12/31/2023	3/31/2024	6/30/2024	9/30/2024	12/31/2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	21.98%	0.70%	18.01%	43.51%	50.13%	78.83%	32.50%	46.22%	43.75%	83.83%
EBITDA Growth	29.51%	148.93%	1,217.18%	3,128.50%	319.31%	-114.33%	-158.73%	-10.93%	0.67%	5,065.16%
EBIT Growth	18.65%	124.22%	257.83%	327.41%	143.05%	-434.79%	-657.06%	-27.51%	-14.46%	354.03%
NOPAT Growth	97.47%	-44.73%	-42.41%	39.17%	1,955.32%	-91.93%	-672.56%	-34.95%	-24.25%	509.01%
Net Income Growth	22.38%	114.22%	-172.48%	32.22%	32.07%	-967.11%	-104.20%	-53.06%	3.89%	174.08%
EPS Growth	0.00%	0.00%	0.00%	39.13%	45.83%	0.00%	-72.73%	-28.57%	7.69%	173.08%
Operating Cash Flow Growth	80.25%	-149.13%	-949.43%	-6.05%	-194.63%	334.27%	43.66%	-160.14%	344.29%	-304.45%
Free Cash Flow Firm Growth	-24.99%	-139.91%	-2,140.19%	-601.87%	-1,450.41%	-660.71%	94.51%	93.79%	83.79%	60.81%
Invested Capital Growth	51.61%	78.48%	0.00%	494.92%	535.20%	361.39%	2.63%	5.74%	14.04%	39.51%
Revenue Q/Q Growth	-2.14%	-10.93%	28.40%	28.22%	2.38%	6.10%	-4.86%	41.50%	0.65%	35.68%
EBITDA Q/Q Growth	-1,392.00%	201.51%	78.27%	38.09%	-12.23%	-106.63%	-630.32%	309.43%	-0.80%	227.24%
EBIT Q/Q Growth	-276.36%	141.30%	-16.62%	75.46%	-28.75%	-421.18%	-38.73%	122.83%	-15.93%	853.81%
NOPAT Q/Q Growth	-105.56%	-2,602.13%	147.64%	94.38%	-25.85%	-379.53%	-42.11%	122.08%	-13.66%	1,409.42%
Net Income Q/Q Growth	-3.61%	116.32%	-729.67%	36.34%	-3.83%	-108.34%	-48.28%	52.28%	34.81%	260.59%
EPS Q/Q Growth	-4.35%	0.00%	0.00%	36.36%	7.14%	-100.00%	-46.15%	52.63%	33.33%	258.33%
Operating Cash Flow Q/Q Growth	-108.44%	-805.37%	-121.28%	155.59%	-126.46%	819.87%	-153.22%	40.67%	207.47%	-702.47%
Free Cash Flow Firm Q/Q Growth	48.15%	-77.59%	-831.06%	18.13%	-14.54%	12.87%	93.50%	7.35%	-198.86%	-110.59%
Invested Capital Q/Q Growth	5.48%	24.93%	355.68%	-0.92%	12.63%	-9.26%	-1.26%	2.07%	21.47%	11.01%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	70.55%	69.67%	68.31%	70.12%	70.62%	68.91%	69.49%	74.38%	75.60%	78.85%
EBITDA Margin	-11.32%	12.90%	17.91%	19.29%	16.54%	-1.03%	-7.94%	11.75%	11.58%	27.93%
Operating Margin	-0.41%	-8.75%	4.64%	7.03%	5.09%	-13.41%	-20.03%	3.13%	2.68%	19.30%
EBIT Margin	-15.76%	7.31%	4.75%	6.50%	4.52%	-13.68%	-19.96%	3.22%	2.69%	18.91%
Profit (Net Income) Margin	-28.32%	5.19%	-25.45%	-12.64%	-12.81%	-25.16%	-39.22%	-13.23%	-8.57%	10.14%
Tax Burden Percent	100.54%	100.00%	95.84%	99.65%	153.96%	94.47%	100.00%	111.26%	100.48%	108.21%
Interest Burden Percent	178.68%	71.00%	-559.40%	-195.22%	-184.12%	194.63%	196.54%	-369.16%	-316.98%	49.56%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-8.21%
Return on Invested Capital (ROIC)	-1.02%	-26.41%	3.51%	5.10%	3.68%	-11.58%	-11.20%	1.93%	1.55%	20.06%
ROIC Less NNEP Spread (ROIC-NNEP)	-39.95%	1.22%	-6.49%	-1.78%	-4.06%	-21.68%	-17.76%	-3.68%	-2.17%	14.86%
Return on Net Nonoperating Assets (RNNOA)	-76.81%	0.65%	-45.18%	-11.09%	-7.73%	-25.20%	-57.71%	-12.33%	-4.51%	29.34%
Return on Equity (ROE)	-77.83%	-25.76%	-41.68%	-5.99%	-4.05%	-36.78%	-68.91%	-10.40%	-2.96%	49.40%
Cash Return on Invested Capital (CROIC)	-35.58%	-51.79%	-199.16%	-141.25%	-143.36%	-128.46%	-5.71%	-9.00%	-16.18%	-30.02%
Operating Return on Assets (OROA)	-13.82%	5.07%	2.02%	4.14%	2.68%	-7.59%	-10.79%	1.87%	1.43%	10.77%
Return on Assets (ROA)	-24.83%	3.60%	-10.83%	-8.06%	-7.60%	-13.95%	-21.20%	-7.68%	-4.55%	5.77%
Return on Common Equity (ROCE)	-81.07%	-26.23%	-42.36%	-6.15%	-4.09%	-37.04%	-69.50%	-10.49%	-2.98%	49.65%
Return on Equity Simple (ROE_SIMPLE)	-1,853.66%	0.00%	-83.59%	-72.66%	-18.75%	0.00%	-51.74%	-57.37%	-57.62%	0.00%
Net Operating Profit after Tax (NOPAT)	-0.07	-1.78	0.85	1.65	1.22	-3.41	-4.85	1.07	0.92	14
NOPAT Margin	-0.29%	-8.75%	3.24%	4.92%	3.56%	-9.39%	-14.02%	2.19%	1.88%	20.88%
Net Nonoperating Expense Percent (NNEP)	38.93%	-27.62%	10.00%	6.88%	7.74%	10.11%	6.56%	5.61%	3.72%	5.21%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-1.33%	-	-	-	4.82%
Cost of Revenue to Revenue	29.45%	30.33%	31.69%	29.88%	29.38%	31.09%	30.51%	25.62%	24.40%	21.15%
SG&A Expenses to Revenue	67.57%	74.96%	60.87%	59.63%	61.38%	72.10%	83.31%	65.01%	68.31%	52.06%
R&D to Revenue	3.40%	3.46%	2.81%	3.47%	4.15%	9.18%	6.21%	6.24%	4.61%	7.12%
Operating Expenses to Revenue	70.96%	78.42%	63.68%	63.10%	65.53%	82.32%	89.52%	71.25%	72.92%	59.55%
Earnings before Interest and Taxes (EBIT)	-3.60	1.49	1.24	2.17	1.55	-4.98	-6.90	1.58	1.33	13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-2.58	2.62	4.68	6.46	5.67	-0.38	-2.75	5.75	5.71	19
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	268.48	14.66	28.98	25.60	6.66	5.56	7.73	0.01	27.52	17.15
Price to Tangible Book Value (P/TBV)	0.00	283.75	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Revenue (P/Rev)	3.69	4.57	6.85	5.58	4.42	3.02	3.37	0.00	9.43	5.99
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	11.81	11.02	4.57	4.25	3.24	2.86	3.32	0.68	8.05	5.65
Enterprise Value to Revenue (EV/Rev)	4.02	4.68	8.46	7.02	5.43	3.81	4.21	0.79	10.38	6.85
Enterprise Value to EBITDA (EV/EBITDA)	0.00	698.05	159.43	64.53	31.93	30.20	64.78	14.68	210.63	49.94
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	554.12	96.17	0.00	0.00	0.00	0.00	158.31
Enterprise Value to NOPAT (EV/NOPAT)	261.60	308.67	1,088.96	609.39	251.09	1,644.29	0.00	0.00	0.00	221.41
Enterprise Value to Operating Cash Flow (EV/OCF)	90.56	243.19	0.00	0.00	0.00	129.19	78.53	1,067.97	410.82	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	93.34	4.12	8.21	8.05	2.52	2.64	3.18	3.31	4.04	3.18
Long-Term Debt to Equity	92.53	4.09	8.17	8.01	2.51	2.64	3.17	3.29	3.39	3.17
Financial Leverage	1.92	0.54	6.96	6.23	1.90	1.16	3.25	3.35	2.08	1.97
Leverage Ratio	11.80	6.70	10.10	11.73	5.05	4.81	6.28	6.61	4.79	5.02
Compound Leverage Factor	21.09	4.76	-56.52	-22.91	-9.30	9.36	12.34	-24.42	-15.19	2.49
Debt to Total Capital	98.94%	80.47%	89.14%	88.94%	71.56%	72.53%	76.10%	76.78%	80.18%	76.05%
Short-Term Debt to Total Capital	0.86%	0.52%	0.38%	0.38%	0.30%	0.00%	0.32%	0.31%	12.90%	0.17%
Long-Term Debt to Total Capital	98.08%	79.95%	88.77%	88.56%	71.26%	72.53%	75.78%	76.47%	67.27%	75.88%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	-0.44%	-0.25%	-0.18%	-0.18%	-0.13%	-0.14%	-0.14%	-0.14%	-0.12%	-0.12%
Common Equity to Total Capital	1.50%	19.79%	11.04%	11.23%	28.58%	27.61%	24.05%	23.37%	19.94%	24.07%
Debt to EBITDA	-10.89	188.94	35.96	15.88	9.77	11.32	21.29	23.18	27.97	8.04
Net Debt to EBITDA	-3.96	17.46	30.49	13.22	5.96	6.28	12.85	14.63	19.25	6.31
Long-Term Debt to EBITDA	-10.79	187.72	35.81	15.81	9.73	11.32	21.20	23.09	23.47	8.02
Debt to NOPAT	59.19	83.55	245.60	149.97	76.82	616.13	-35.53	-32.22	-37.19	35.63
Net Debt to NOPAT	21.51	7.72	208.24	124.89	46.90	341.79	-21.44	-20.33	-25.61	27.98
Long-Term Debt to NOPAT	58.67	83.01	244.56	149.32	76.50	616.13	-35.38	-32.09	-31.21	35.55
Altman Z-Score	1.76	2.25	1.83	1.64	1.63	1.09	1.23	0.15	3.30	2.62
Noncontrolling Interest Sharing Ratio	-4.15%	-1.86%	-1.65%	-2.59%	-0.93%	-0.73%	-0.87%	-0.89%	-0.53%	-0.51%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	3.49	6.35	2.92	2.62	5.80	2.83	3.00	2.60	1.55	2.08
Quick Ratio	3.04	5.80	2.20	2.08	4.85	2.41	2.51	2.30	1.33	1.79
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-10	-18	-171	-140	-160	-139	-9.36	-8.68	-26	-55
Operating Cash Flow to CapEx	-38.86%	-422.78%	-1,656.05%	1,826.40%	-232.31%	4,482.47%	-5,030.43%	-798.26%	488.58%	-3,203.42%
Free Cash Flow to Firm to Interest Expense	-5.73	-9.86	-16.70	-24.48	-27.81	-27.19	-1.73	-1.59	-4.69	-8.56
Operating Cash Flow to Interest Expense	-0.23	-2.00	-0.80	0.80	-0.21	1.70	-0.85	-0.50	0.53	-2.79
Operating Cash Flow Less CapEx to Interest Expense	-0.81	-2.47	-0.85	0.76	-0.30	1.66	-0.87	-0.56	0.42	-2.88
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.88	0.69	0.43	0.64	0.59	0.55	0.54	0.58	0.53	0.57
Accounts Receivable Turnover	16.23	16.53	7.64	8.21	9.06	6.13	6.75	4.39	4.69	2.62
Inventory Turnover	5.28	4.72	3.05	4.55	4.86	4.55	4.21	4.95	4.87	4.57
Fixed Asset Turnover	21.79	26.74	25.82	31.98	33.00	37.16	39.76	44.54	46.63	55.03
Accounts Payable Turnover	2.27	2.52	2.01	2.31	2.57	2.07	2.90	2.22	2.44	1.49
Days Sales Outstanding (DSO)	22.49	22.08	47.75	44.44	40.30	59.59	54.05	83.17	77.91	139.55
Days Inventory Outstanding (DIO)	69.16	77.35	119.86	80.17	75.15	80.15	86.64	73.80	75.03	79.93
Days Payable Outstanding (DPO)	161.09	144.57	181.82	158.29	142.20	176.57	125.91	164.54	149.62	244.55
Cash Conversion Cycle (CCC)	-69.43	-45.14	-14.22	-33.68	-26.75	-36.84	14.78	-7.57	3.32	-25.06
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	30	38	171	170	191	174	176	180	218	242
Invested Capital Turnover	3.54	3.02	1.08	1.04	1.03	1.23	0.80	0.88	0.83	0.96
Increase / (Decrease) in Invested Capital	10	17	171	141	161	136	4.51	9.75	27	69
Enterprise Value (EV)	356	415	784	721	620	496	583	122	1,755	1,367
Market Capitalization	327	405	634	574	505	393	468	0.74	1,595	1,195
Book Value per Share	$0.05	$1.01	$0.73	$0.74	$2.16	$2.02	$1.71	$1,654.33	$1.63	$1.96
Tangible Book Value per Share	($0.76)	$0.05	($4.43)	($4.32)	($2.55)	($2.61)	($2.80)	($2,788.22)	($3.76)	($3.30)
Total Capital	81	139	198	199	265	256	252	251	291	289
Total Debt	80	112	177	177	190	186	192	192	233	220
Total Long-Term Debt	80	112	176	177	189	186	191	192	196	220
Net Debt	29	10	150	148	116	103	116	121	160	173
Capital Expenditures (CapEx)	1.06	0.88	0.50	0.25	0.52	0.19	0.09	0.34	0.60	0.56
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.72	-1.51	7.84	8.38	18	7.37	8.53	16	17	52
Debt-free Net Working Capital (DFNWC)	46	100	35	38	92	90	85	87	90	99
Net Working Capital (NWC)	46	100	34	37	91	90	84	86	52	98
Net Nonoperating Expense (NNE)	6.40	-2.83	7.49	5.88	5.61	5.74	8.72	7.54	5.14	7.18
Net Nonoperating Obligations (NNO)	29	10	150	148	116	103	116	121	160	173
Total Depreciation and Amortization (D&A)	1.01	1.14	3.44	4.28	4.12	4.60	4.16	4.18	4.38	6.03
Debt-free, Cash-free Net Working Capital to Revenue	-3.07%	-1.70%	8.47%	8.16%	15.91%	5.66%	6.15%	10.14%	10.03%	25.83%
Debt-free Net Working Capital to Revenue	52.46%	113.27%	37.51%	37.04%	80.61%	69.23%	60.93%	56.18%	52.95%	49.50%
Net Working Capital to Revenue	51.67%	112.45%	36.70%	36.30%	79.93%	69.23%	60.36%	55.69%	30.78%	49.25%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.24)	$0.05	($0.22)	($0.14)	($0.13)	($0.26)	($0.38)	($0.18)	($0.12)	$0.19
Adjusted Weighted Average Basic Shares Outstanding	27.35M	27.46M	30.12M	30.46M	34.26M	32.62M	35.47M	35.62M	35.70M	35.65M
Adjusted Diluted Earnings per Share	$0.00	$0.00	$0.00	($0.14)	($0.13)	($0.26)	($0.38)	($0.18)	($0.12)	$0.19
Adjusted Weighted Average Diluted Shares Outstanding	27.41M	27.46M	30.29M	30.46M	34.26M	32.62M	35.47M	35.62M	35.70M	35.65M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.41M	29.97M	30.12M	35.12M	35.12M	35.36M	35.38K	35.48M	35.61M	35.65M
Normalized Net Operating Profit after Tax (NOPAT)	-0.07	-1.24	0.85	1.65	1.22	-3.41	-4.85	1.07	0.92	9.03
Normalized NOPAT Margin	-0.29%	-6.12%	3.24%	4.92%	3.56%	-9.39%	-14.02%	2.19%	1.88%	13.51%
Pre Tax Income Margin	-28.17%	5.19%	-26.55%	-12.68%	-8.32%	-26.63%	-39.22%	-11.89%	-8.53%	9.37%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2.00	0.80	0.12	0.38	0.27	-0.97	-1.27	0.29	0.24	1.98
NOPAT to Interest Expense	-0.04	-0.96	0.08	0.29	0.21	-0.67	-0.90	0.20	0.17	2.19
EBIT Less CapEx to Interest Expense	-2.59	0.33	0.07	0.34	0.18	-1.01	-1.29	0.23	0.13	1.90
NOPAT Less CapEx to Interest Expense	-0.62	-1.43	0.03	0.24	0.12	-0.70	-0.91	0.13	0.06	2.10
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Harrow Health, Inc. 11.875% Senior Notes due 2027's Financials

When does Harrow Health, Inc. 11.875% Senior Notes due 2027's financial year end?

According to the most recent income statement we have on file, Harrow Health, Inc. 11.875% Senior Notes due 2027's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Harrow Health, Inc. 11.875% Senior Notes due 2027's net income changed over the last 10 years?

Harrow Health, Inc. 11.875% Senior Notes due 2027's net income appears to be on an upward trend, with a most recent value of -$17.48 million in 2024, rising from -$10.12 million in 2014. The previous period was -$24.41 million in 2023.

What is Harrow Health, Inc. 11.875% Senior Notes due 2027's operating income?

Harrow Health, Inc. 11.875% Senior Notes due 2027's total operating income in 2024 was $8.82 million, based on the following breakdown:

Total Gross Profit: $150.37 million
Total Operating Expenses: $141.55 million

How has Harrow Health, Inc. 11.875% Senior Notes due 2027 revenue changed over the last 10 years?

Over the last 10 years, Harrow Health, Inc. 11.875% Senior Notes due 2027's total revenue changed from $1.66 million in 2014 to $199.61 million in 2024, a change of 11,924.9%.

How much debt does Harrow Health, Inc. 11.875% Senior Notes due 2027 have?

Harrow Health, Inc. 11.875% Senior Notes due 2027's total liabilities were at $319.67 million at the end of 2024, a 32.2% increase from 2023, and a 15,180.8% increase since 2014.

How much cash does Harrow Health, Inc. 11.875% Senior Notes due 2027 have?

In the past 10 years, Harrow Health, Inc. 11.875% Senior Notes due 2027's cash and equivalents has ranged from $0.00 in 2017 to $96.27 million in 2022, and is currently $47.25 million as of their latest financial filing in 2024.

How has Harrow Health, Inc. 11.875% Senior Notes due 2027's book value per share changed over the last 10 years?

Over the last 10 years, Harrow Health, Inc. 11.875% Senior Notes due 2027's book value per share changed from 0.88 in 2014 to 1.96 in 2024, a change of 122.1%.

Related Companies

This page (NASDAQ:HROWM) was last updated on 5/4/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Financials

Frequently Asked Questions About Harrow Health, Inc. 11.875% Senior Notes due 2027's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Harrow Health, Inc. 11.875% Senior Notes due 2027 (HROWM) Financials

Annual Income Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

Quarterly Income Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

Annual Cash Flow Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

Quarterly Cash Flow Statements for Harrow Health, Inc. 11.875% Senior Notes due 2027

Annual Balance Sheets for Harrow Health, Inc. 11.875% Senior Notes due 2027

Quarterly Balance Sheets for Harrow Health, Inc. 11.875% Senior Notes due 2027

Annual Metrics and Ratios for Harrow Health, Inc. 11.875% Senior Notes due 2027

Quarterly Metrics and Ratios for Harrow Health, Inc. 11.875% Senior Notes due 2027

Frequently Asked Questions About Harrow Health, Inc. 11.875% Senior Notes due 2027's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools